How does ERS have the ability to license these patents?
为什么ERS有权授权这些专利?
Via direct license from Emmanuelle Charpentier (to her co-ownership rights in the CVC patents), ERS Genomics has the right to provide licenses to this fundamental portfolio of foundational CRISPR/Cas9 patents. A license from ERS provides access to the full CVC portfolio and no other license from any of the other co-owners (University of California or University of Vienna) is required. ERS is the only company whose sole focus is on out-licensing to maximize commercial access to the CVC global patent portfolio.
通过Emmanuelle Charpentier的直接授权（对她在CVC专利中的共同所有权），ERS Genomics公司有权为这个基础性的CRISPR/Cas9专利组合提供授权。 ERS的许可证提供了对CVC全部资产的访问，不需要其他任何共同所有者（加利福尼亚大学或维也纳大学）的许可证。 ERS是唯一一家只专注于对外授权的公司，以最大限度地将CVC的全球专利组合用于商业用途。